DTCF Expands into Life Sciences with Investment in Nuclidium’s €84 Million Series B

DeepTech & Climate Fonds (DTCF) has taken a big step into Life Sciences by joining Nuclidium’s €84 million (CHF 79 million) Series B financing. The round, led by a strong syndicate of European investors, Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK and HighLight Capital, as well as existing investors, will help Nuclidium advance clinical development of its copper-based radiopharmaceuticals and expand global production.

For DTCF, the investment reflects its strategy to support breakthrough technologies that combine deep science with global impact. After building a portfolio across DTCF, the fund is now extending its reach into healthcare innovation.

A New Era for Radiotheranostics

Nuclidium’s platform pairs Copper-61 for imaging with Copper-67 for therapy, creating a seamless link between diagnosis and treatment. Early clinical data already show the potential for better imaging performance and higher precision than current standards.

“Nuclidium is entering the next clinical phases with its lead compounds to diagnose and treat metastatic prostate, neuroendocrine tumors and breast cancer,” said Leila Jaafar, PhD, CEO and Co-Founder of Nuclidium. “Our copper-based radiotheranostics are designed to integrate smoothly into hospital workflows, making them more accessible worldwide. We also see huge potential to expand into cancers highly relevant to women’s health.”

For DTCF, Nuclidium represents exactly the kind of transformative company it seeks to back.

“We are delighted to support Nuclidium as part of this EUR 84 million Series B round backed by European investors,” said Tobias Faupel, Managing Director at DTCF. “Their platform enables a seamless transition from diagnosis with Cu-61 to therapy with Cu-67 while addressing structural bottlenecks in radiopharmacy. Early data confirm the potential for improved imaging and efficacy, positioning Nuclidium as a next-generation leader in the field.”

Dr. Christopher Jahn, Investment Associate at DTCF, added: “Nuclidium’s breakthrough, 61Cu-NuriPro™, was able to detect additional tumor lesions in 50% of patients that existing methods missed in early trials. With 67Cu-NuriPro™, these lesions can be treated directly, opening new treatment options for cancer patients. We’re eager to be part of the journey.”

Looking Ahead

As Nuclidium builds its production network and deepens collaborations with hospitals and academic centers in Europe and North America, DTCF will support the company with capital, expertise, and long-term commitment.

With this investment, DTCF not only broadens its portfolio but also reinforces its mission: to back bold innovators shaping the future of industries and societies.

More information for Media

Original Press Release English (PDF)
Original Press Release German (PDF)

For media requests please contact:
Nuclidium: Stephanie May, nuclidium@trophic.eu
DeepTech & Climate Fonds: Stephanie Stein, s.stein@dtcf.de

About NUCLIDIUM
NUCLIDIUM AG is a clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – NUCLIDIUM is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. The company’s operations in Switzerland and Germany combine innovative chemistry, deep clinical expertise, and strategic manufacturing capabilities to deliver scalable, accessible, and clinically superior theranostic solutions to patients worldwide. NUCLIDIUM is committed to expanding the reach and efficacy of radiotheranostics, including addressing critical unmet medical needs in oncology and women’s health.

About DeepTech & Climate Fonds
The DeepTech & Climate Fonds (DTCF) invests up to €50 million in high-growth deep-tech and climate-tech companies in Germany and Europe. As an anchor investor and partner of long-term-oriented European investors, DTCF supports companies with extended development cycles and substantial financial needs in implementing sustainable growth strategies and actively contributes to expanding the technology ecosystem. The fund acts as a bridge between investors, SMEs, and innovative high-tech startups in the fields of climate, computing, industry, and life sciences. Funded by resources from the German Future Fund and the ERP Special Fund, DTCF plans to invest €1 billion over the coming years to strengthen the European technology ecosystem. More information